Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder
PsiquiatriaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Drug and alcohol dependence
- Publicado em
- 23 abr 2023
- Citações
- 10
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Cost-effectiveness of flexible take-home buprenorphine-naloxone versus methadone for treatment of prescription-type opioid use disorder
Benjamin Enns, Emanuel Krebs, David G T Whitehurst, Didier Jutras-Aswad, Bernard Le Foll, M Eugenia Socias, Bohdan Nosyk, OPTIMA Research Group within the Canadian Research Initiative in Substance Misuse
Descritores MeSH
- Buprenorphine
- Opioid-Related Disorders
- Cost-Benefit Analysis
- Humans
- Methadone
- Narcotic Antagonists
- Prescriptions
- Buprenorphine, Naloxone Drug Combination
- Opiate Substitution Treatment
- Analgesics, Opioid
Veja também
Estudos relacionados
- Associations of Methadone and BUP/NX Dose Titration Patterns With Retention in Treatment and Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: Secondary Analysis of the OPTIMA Study
- Associations of methadone and buprenorphine-naloxone doses with unregulated opioid use, treatment retention, and adverse events in prescription-type opioid use disorders: Exploratory analyses of the OPTIMA study
- Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial
- Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial